Nebenwirkungen · Revestive
Revestive 1.25 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 8
HOS-215152 · Präparat HOS-155390
Modest increases of C-reactive protein of approximately 25 mg/l have been observed within the first seven days of teduglutide treatment, which decreased continuously under ongoing daily injections. After 24 weeks of teduglutide treatment, patients showed small overall increase in C-reactive protein of approximately 1.5 mg/l on average. These changes were neither associated with any changes in other laboratory parameters nor with any reported clinical symptoms. There were no clinically relevant mean increases of C-reactive protein from baseline following long-term treatment with teduglutide for up to 30 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-23T08:51:00Z · SHA-256 ee78036578e80de286e3ba966c724bcc7d52c762c5f1b64fe55e22c6b675997f · Passage 9710a25de853e9670447169df25ce7702425a7f5daecd30101fa849933dc0c00 · Zeichen 5730–6347 im Abschnitt